These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 2239943)

  • 1. The role of aluminum in the functional iron deficiency of patients treated with erythropoietin: case report of clinical characteristics and response to treatment.
    Donnelly SM; Smith EK
    Am J Kidney Dis; 1990 Nov; 16(5):487-90. PubMed ID: 2239943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioavailability of iron in hemodialysis patients treated with erythropoietin: evidence for the inhibitory role of aluminum.
    Donnelly SM; Ali MA; Churchill DN
    Am J Kidney Dis; 1990 Nov; 16(5):447-51. PubMed ID: 2239935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of deferoxamine on erythropoiesis in patients hemodialyzed for chronic renal insufficiency treated with erythropoietin].
    Kalinowski M; Popławski A; Kaliszewski Z; Juzwiuk J
    Pol Merkur Lekarski; 1996 Oct; 1(4):232-4. PubMed ID: 9156931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Erythropoietin resistance].
    Branger B
    Nephrologie; 2002; 23(1):3-5. PubMed ID: 11887576
    [No Abstract]   [Full Text] [Related]  

  • 5. Variations in erythropoiesis and serum ferritin during erythropoietin therapy for anaemia of end-stage renal disease.
    Barosi G; Merlo C; Palestra P; Liberato NL; Guarnone R; Di Dio F; Piazza V; Salvadeo A
    Acta Haematol; 1993; 90(1):13-8. PubMed ID: 8237268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Aluminum and iron deposition in dialysis patients].
    Kurihara S; Marumo F
    Nihon Rinsho; 1992 Jan; 50 Suppl():905-10. PubMed ID: 1578787
    [No Abstract]   [Full Text] [Related]  

  • 7. Reasons for differences in dose requirements of recombinant human erythropoietin in haemodialysis patients.
    Scigalla P; Messinger D; Wieczorek L
    Contrib Nephrol; 1990; 82():55-64. PubMed ID: 2093527
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of recombinant human erythropoietin on iron balance in maintenance hemodialysis: theoretical considerations, clinical experience and consequences.
    Grützmacher P; Tsobanelis T; Roth P; Werner E; Vlachojannis J; Kaltwasser J; Kurz P; Scheuermann EH; Schoeppe W
    Clin Nephrol; 1992; 38 Suppl 1():S92-7. PubMed ID: 1295714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low dose desferrioxamine can improve erythropoiesis in iron-overload hemodialysis patients without side effects.
    Lee CT; Liao SC; Hsu KT; Lam KK; Chen JB
    Ren Fail; 1999 Nov; 21(6):665-73. PubMed ID: 10586429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of iron deficiency in renal anemia: guidelines for the optimal therapeutic approach in erythropoietin-treated patients.
    Drüeke TB; Bárány P; Cazzola M; Eschbach JW; Grützmacher P; Kaltwasser JP; Macdougall IC; Pippard MJ; Shaldon S; van Wyck D
    Clin Nephrol; 1997 Jul; 48(1):1-8. PubMed ID: 9247771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erythropoietin hyporesponsiveness: from iron deficiency to iron overload.
    Tarng DC; Huang TP; Chen TW; Yang WC
    Kidney Int Suppl; 1999 Mar; 69():S107-18. PubMed ID: 10084294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Factors affecting the response to erythropoiesis-stimulating agents].
    Jauréguy M; Choukroun G
    Nephrol Ther; 2006 Sep; 2 Suppl 4():S274-82. PubMed ID: 17373270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone marrow amyloidosis with erythropoietin-resistant anemia in a patient undergoing chronic hemodialysis treatment.
    Cetinkaya R; Odabas AR; Selcuk Y; Erman Z; Kaya H
    South Med J; 2003 May; 96(5):491-3. PubMed ID: 12911189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The anemia of chronic renal failure: pathophysiology and effects of recombinant erythropoietin.
    Eschbach JW; Haley NR; Adamson JW
    Contrib Nephrol; 1990; 78():24-36; discussion 37. PubMed ID: 2225841
    [No Abstract]   [Full Text] [Related]  

  • 15. Effects of azathioprine on response of renal anaemia to subcutaneous recombinant human erythropoietin.
    Howarth JE; Waters HM; Shanks D; Hyde K; Yin JA; Geary CG; Anastassiades E; Howarth D; Gokal R
    J Clin Pathol; 1993 Jan; 46(1):41-4. PubMed ID: 8432886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical efficacy of recombinant human erythropoietin in the treatment of anemia in hemodialysis patients: influence of dosing regimen, iron status, and serum aluminum.
    Tsai JC; Lai YH; Tsai ZY; Chien LJ; Tsai JH
    Gaoxiong Yi Xue Ke Xue Za Zhi; 1991 Mar; 7(3):126-35. PubMed ID: 1865507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of subcutaneous low-dose erythropoietin in patients with chronic renal failure despite functional iron deficiency.
    Bedani PL; Cecchetti E; Gilli P
    Nephron; 1995; 71(4):459-60. PubMed ID: 8587628
    [No Abstract]   [Full Text] [Related]  

  • 18. Maintenance therapy with intravenous iron in hemodialysis patients receiving erythropoietin.
    Kotaki M; Uday K; Henriquez M; Blum S; Dave M
    Clin Nephrol; 1997 Jul; 48(1):63-4. PubMed ID: 9247787
    [No Abstract]   [Full Text] [Related]  

  • 19. Iron status in patients receiving erythropoietin for dialysis-associated anemia.
    Van Wyck DB; Stivelman JC; Ruiz J; Kirlin LF; Katz MA; Ogden DA
    Kidney Int; 1989 Feb; 35(2):712-6. PubMed ID: 2709674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant human erythropoietin reduces free erythrocyte protoporphyrin levels in patients on chronic dialysis.
    Piazza V; Villa G; Galli F; Segagni S; Bovio G; Poggio F; Picardi L; Salvadeo A
    Nephron; 1992; 61(1):54-7. PubMed ID: 1528341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.